Second line options for hyperlipidemia management after cardiac transplantation
Cardiovascular Therapeutics, 05/04/2012Shah MKH et al.
Unfortunately the solution is not easy, with problems of toleration at higher statin doses and a lack of good quality evidence for second line agents. Authors review the literature and discuss some of the key issues transplant physicians are faced with when considering alternatives to statin therapy.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.